Multiple Sclerosis Journal · 2002 · 18 citations · 41 references
Life SciencesNeurologyPharmacotherapyAutoimmunityInflammationNeuroimmunologyDemyelinating DiseasesDemyelinating DisordersImmune-mediated DiseaseInterferon-based TherapyMultiple SclerosisNeuroinflammationEarly Treatment Response AssessmentEarly Treatment WindowInterferon Response KineticsMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis ImmunopathologyMultiple Sclerosis PathologyMultiple Sclerosis TherapyNeuroinflammation In Multiple Sclerosis
The current approach to the use of interferon (IFN) beta in the treatment of multiple sclerosis (MS) is, in general, conservative. However, recent findings about early events in MS and data on dose-response relationships with IFN beta indicate that such an approach may be suboptimal. Four lines of evidence suggest that delays in the initiation of therapy with IFN beta may be detrimental: I) axonal damage secondary to inflammation starts very early in the course of MS; 2) pathological events occurring early in MS are predictive of the future course of the disease; 3) inflammatory activity in relapsing MS is not confined to episodes of clinical impairment, but often starts before the first such episode and generally continues during remissions; and 4) the immune-mediated activity that underlies MS may become more difficult to control as the disease progresses. An early treatment strategy is also supported by data from two recently published clinical studies. In addition, preclinical and clinical results suggest that the beneficial effects of IFN may be dose- and frequency-dependent Taken together, these findings indicate that treatment with IFN beta should be started as early as possible in the course of MS, and suggest that, in order to maximize patient benefit, the highest possible dose of IFN beta should be chosen. Multiple Sclerosis (2002) 8, 2-9
41
Axonal Transection in the Lesions of Multiple Sclerosis
Bruce D. Trapp, John W. Peterson, Richard M. Ransohoff et al. · New England Journal of Medicine · 1998 · 4K citations · Full text
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Neurology · 1993 · 2.1K citations
Pharmacy, Neurology, Pharmacotherapy +14
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
D. W. Paty, D.K.B. Li · Neurology · 1993 · 2K citations · Full text
Pharmacy, Neurology, Pharmacotherapy +14